Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Janux Therapeutics Inc (NQ: JANX ) 43.99 +1.23 (+2.88%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Janux Therapeutics Inc < Previous 1 2 Next > Janux Therapeutics Announces Updates to Board of Directors July 22, 2024 From Janux Therapeutics Via Business Wire Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 07, 2024 From Janux Therapeutics Via Business Wire Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights March 08, 2024 From Janux Therapeutics Via Business Wire Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants February 29, 2024 From Janux Therapeutics Via Business Wire Janux Therapeutics Announces Proposed Public Offering of Common Stock February 27, 2024 From Janux Therapeutics Via Business Wire Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors February 26, 2024 From Janux Therapeutics Via Business Wire Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 February 20, 2024 From Janux Therapeutics Via Business Wire Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer January 08, 2024 From Janux Therapeutics Via Business Wire Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights November 07, 2023 From Janux Therapeutics Via Business Wire Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights August 08, 2023 From Janux Therapeutics Via Business Wire Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants July 17, 2023 From Janux Therapeutics Via Business Wire Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs July 17, 2023 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development June 05, 2023 From Janux Therapeutics Via Business Wire Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights May 09, 2023 From Janux Therapeutics Via Business Wire Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences April 24, 2023 From Janux Therapeutics Via Business Wire Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors April 20, 2023 From Janux Therapeutics Via Business Wire Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights March 10, 2023 From Janux Therapeutics Via Business Wire Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference February 14, 2023 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors December 27, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics to Present at Upcoming Investor Conferences in November November 22, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights November 10, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer October 12, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources September 23, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Appoints Winston Kung to Board of Directors September 22, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September August 31, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights August 09, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference June 02, 2022 From Janux Therapeutics Via Business Wire Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer May 31, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights May 10, 2022 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr April 26, 2022 From Janux Therapeutics Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
